JP2015509522A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509522A5
JP2015509522A5 JP2014560382A JP2014560382A JP2015509522A5 JP 2015509522 A5 JP2015509522 A5 JP 2015509522A5 JP 2014560382 A JP2014560382 A JP 2014560382A JP 2014560382 A JP2014560382 A JP 2014560382A JP 2015509522 A5 JP2015509522 A5 JP 2015509522A5
Authority
JP
Japan
Prior art keywords
composition according
motomeko
toxoid
composition
tlr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560382A
Other languages
English (en)
Japanese (ja)
Other versions
JP6345603B2 (ja
JP2015509522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/054672 external-priority patent/WO2013132041A2/en
Publication of JP2015509522A publication Critical patent/JP2015509522A/ja
Publication of JP2015509522A5 publication Critical patent/JP2015509522A5/ja
Application granted granted Critical
Publication of JP6345603B2 publication Critical patent/JP6345603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560382A 2012-03-08 2013-03-08 追加免疫ワクチンのアジュバント化された処方物 Active JP6345603B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261608398P 2012-03-08 2012-03-08
US61/608,398 2012-03-08
US201261697730P 2012-09-06 2012-09-06
US61/697,730 2012-09-06
PCT/EP2013/054672 WO2013132041A2 (en) 2012-03-08 2013-03-08 Adjuvanted formulations of booster vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017096343A Division JP2017132821A (ja) 2012-03-08 2017-05-15 追加免疫ワクチンのアジュバント化された処方物

Publications (3)

Publication Number Publication Date
JP2015509522A JP2015509522A (ja) 2015-03-30
JP2015509522A5 true JP2015509522A5 (enExample) 2016-04-21
JP6345603B2 JP6345603B2 (ja) 2018-06-20

Family

ID=47843287

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014560382A Active JP6345603B2 (ja) 2012-03-08 2013-03-08 追加免疫ワクチンのアジュバント化された処方物
JP2017096343A Withdrawn JP2017132821A (ja) 2012-03-08 2017-05-15 追加免疫ワクチンのアジュバント化された処方物
JP2018194314A Pending JP2019001832A (ja) 2012-03-08 2018-10-15 追加免疫ワクチンのアジュバント化された処方物
JP2021015094A Active JP7295895B2 (ja) 2012-03-08 2021-02-02 追加免疫ワクチンのアジュバント化された処方物
JP2023045185A Pending JP2023085364A (ja) 2012-03-08 2023-03-22 追加免疫ワクチンのアジュバント化された処方物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017096343A Withdrawn JP2017132821A (ja) 2012-03-08 2017-05-15 追加免疫ワクチンのアジュバント化された処方物
JP2018194314A Pending JP2019001832A (ja) 2012-03-08 2018-10-15 追加免疫ワクチンのアジュバント化された処方物
JP2021015094A Active JP7295895B2 (ja) 2012-03-08 2021-02-02 追加免疫ワクチンのアジュバント化された処方物
JP2023045185A Pending JP2023085364A (ja) 2012-03-08 2023-03-22 追加免疫ワクチンのアジュバント化された処方物

Country Status (9)

Country Link
US (3) US9375471B2 (enExample)
EP (1) EP2822581A2 (enExample)
JP (5) JP6345603B2 (enExample)
CN (1) CN104159602B (enExample)
AU (1) AU2013229432A1 (enExample)
CA (1) CA2866406A1 (enExample)
MX (1) MX372965B (enExample)
RU (1) RU2014140521A (enExample)
WO (1) WO2013132041A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
AU2010290896B2 (en) * 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
JP6345603B2 (ja) * 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
US20220054615A1 (en) * 2018-12-05 2022-02-24 Sanofi Pasteur Inc. Pertussis booster vaccine
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
WO2025240361A1 (en) * 2024-05-13 2025-11-20 The Board Of Trustees Of The Leland Stanford Junior University Enpp1 and/or enpp3 inhibitors
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67769T1 (de) 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5059258A (en) 1989-08-23 1991-10-22 Aluminum Company Of America Phosphonic/phosphinic acid bonded to aluminum hydroxide layer
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69529219T2 (de) 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
FI972194A7 (fi) 1994-11-24 1997-05-22 Basilea Pharmaceutica Ag Uusia bentsyylipyrimidiinejä
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
US7818252B2 (en) 2003-02-20 2010-10-19 Gilat Satellite Networks, Ltd Enforcement of network service level agreements
AU2004247305B2 (en) 2003-06-16 2010-02-18 Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
WO2005102049A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US8133973B2 (en) 2005-05-12 2012-03-13 Novartis Vaccines And Diagnostics, S.R.L. Immunogenic compositions for Chlamydia trachomatis
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007053455A2 (en) 2005-10-28 2007-05-10 Vaxinnate Corporation Polypeptide ligans for toll-like receptor 4 (tlr4)
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
PT2038290E (pt) 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
WO2008047174A1 (en) 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP2125792B1 (en) 2007-02-19 2010-12-01 GlaxoSmithKline LLC Purine derivatives as immunomodulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2155743B1 (en) 2007-05-08 2012-08-29 AstraZeneca AB Imidazoquinolines with immuno-modulating properties
JP5637848B2 (ja) * 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
UA105764C2 (uk) 2008-03-24 2014-06-25 4 Сц Аг Заміщені імідазохіноліни
WO2010003009A2 (en) 2008-07-01 2010-01-07 Emory University Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
RS51999B (sr) 2008-08-28 2012-04-30 Novartis Ag Dobijanje skvalena iz hiperprodukcijskih kvasaca
TWM352127U (en) 2008-08-29 2009-03-01 Bestac Advanced Material Co Ltd Polishing pad
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
MX338898B (es) 2009-02-17 2016-05-03 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
US8609106B2 (en) 2009-06-01 2013-12-17 Novartis Ag Combinations of pneumococcal RrgB clades
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
EP2498815A4 (en) 2009-11-09 2014-03-19 Nat Jewish Health VACCINE COMPOSITION
EP2506834B1 (en) 2009-12-03 2016-03-02 Novartis AG Circulation of components during homogenization and microfluidization of emulsions
DK2343052T3 (da) 2009-12-03 2013-09-02 Novartis Ag Hydrofil filtrering under fremstilling af vaccineadjuvanter
PL2380558T5 (pl) 2009-12-03 2020-10-05 Novartis Ag Wytwarzanie emulsji w układzie komory oddziaływań i komory przeciwciśnieniowej do mikrofluidyzacji
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
CA2796314A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
AU2011251706B2 (en) 2010-05-12 2015-10-22 Seqirus UK Limited Improved methods for preparing squalene
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
BR112014004782A2 (pt) 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
WO2013131984A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of rabies virus immunogens
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
DK2822947T3 (en) 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
CA2888721A1 (en) 2012-10-25 2014-05-01 Glaxosmithkline Biologicals Sa Nicotinamide as adjuvant

Similar Documents

Publication Publication Date Title
RU2014140521A (ru) Адъювантные составы бустерных вакцин
JP2014506916A5 (enExample)
JP2014525429A5 (enExample)
JP6110845B2 (ja) 耐熱性ワクチン組成物及びそれを調製する方法
CN111212846B (zh) 三萜皂苷类似物
US10188733B2 (en) Vaccines comprising bisphosphonate and methods of use thereof
Kocourkova et al. Vaccine ingredients: components that influence vaccine efficacy
Hawken et al. Adjuvants and inactivated polio vaccine: a systematic review
HRP20230359T1 (hr) Imunogeni pripravak
RU2013144207A (ru) Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
JP2015028032A (ja) ワクチン
CN104093418A (zh) 金黄色葡萄球菌抗原的含佐剂制剂
JPWO2020022272A5 (enExample)
RU2008123006A (ru) Получение вакцин, содержащих поверхностный антиген вируса гепатита в и поверхностно-активное вещество
JP2021001182A5 (enExample)
JP2018500322A5 (enExample)
RU2015106745A (ru) Иммуногенные композиции
Mallet et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety
WO2020118159A1 (en) Methods and compositions comprising an nfkb inhibitor and an adjuvant
JP2015509963A5 (enExample)
AU2019376832B2 (en) Immunogenic compositions
JP2017509713A5 (enExample)
RU2016141621A (ru) Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин
KR20150020164A (ko) 보강제 제형 및 방법
JP2022511511A5 (enExample)